 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

IGM Biosciences  announces reduction in workforce of approximately 22%

IGM Biosciences to resume trading at 4:30 pm ET

IGM Biosciences announces strategic pipeline prioritization and cash runway

Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease All...

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

This indicator may be signaling that IGMS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

IGM Biosciences (IGMS, $5.88) entered Downtrend as Momentum indicator drops below 0 level on Dec 04, 2023

Over the last three days, A.I.dvisor has detected that IGMS's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

IGM Biosciences (IGMS, $5.88) Aroon Indicator entered an Uptrend on December 04, 2023.

IGM Biosciences (IGMS, $6.21) Aroon Indicator entered an Uptrend on December 01, 2023.

Bulletin from Extraordinary General Meeting in Medivir AB (publ) Bulletin from Extraordinary General Meeting in Medivir AB (publ) PR Newswire STOCKHOLM, Dec. 1, 2023 STOCKHOLM, Dec. 1, 2023...

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

IGM Biosciences (IGMS, $6.74) Aroon Indicator entered an Uptrend on November 30, 2023.

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC Medivir announces updated formulation of fostrox, critical to...

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Watchers	1,209
52-Wk Low	$3.81
52-Wk High	$27.92

Market Cap	$343.94M
Volume (M)	379,249.00
52-Wk High	$27.92
52-Wk Low	$3.81

IGMS IGM Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community